Hepatitis B virus immunization in adults
Telemedicine Consult - Dr. Gish
Schedule Telemedicine Consult with Dr. Gish Powered byTelemed2U
Powered byTelemed2U

Hepatitis B virus immunization in adults

Introduction

There are more than two billion individuals with serologic evidence of hepatitis B virus (HBV) infection worldwide [1]. Of these, 240 million are chronic carriers, and approximately 686,000 hepatitis B related deaths occur annually [2-4]. Despite advances in antiviral therapy, only a minority of patients with chronic hepatitis B will have a sustained response. Thus, primary prevention by vaccination to increase herd immunity remains the main focus in controlling HBV infection.

Please see documents below for more information:


Centers for Disease Control and Prevention

Recommendations of the Advisory Committee on Immunization Practices for Use of a Hepatitis B Vaccine with a Novel Adjuvant
View Document


U.S. Food & Drug Administration

Approval Letter
View Letter


UpToDate

Draft Letter to UpToDate
View Letter


UpToDate

Hepatitis B virus immunization in adults
View UpToDate article


Dynavax Technologies Corporation

HEPLISAV-B [Hepatitis B Vaccine (Recombinant), Adjuvanted]
View Document


Metadata